Novel methods to monitor antigen-specific cytotoxic T-cell responses in cancer immunotherapy - PubMed (original) (raw)
Review
Novel methods to monitor antigen-specific cytotoxic T-cell responses in cancer immunotherapy
P Romero et al. Mol Med Today. 1998 Jul.
Abstract
Monitoring cytotoxic T lymphocyte (CTL) responses to tumor antigens that have been defined at the molecular level has become essential to assess novel approaches to the specific immunotherapy of cancer. Nevertheless, because of the low affinity of the interactions between T-cell receptors and their ligands, there are no straightforward, well-standardized methods to meet this need. In this review, we describe several novel methods to track antigen-specific CTL responses.
Similar articles
- [Tumor antigen-specific cytotoxic T lymphocytes and cancer immunotherapy - review].
Liu Y. Liu Y. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2004 Apr;12(2):244-8. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2004. PMID: 15157343 Review. Chinese. - Immunotherapy II: Antigens, receptors and costimulation.
Searle PF, Young LS. Searle PF, et al. Cancer Metastasis Rev. 1996 Sep;15(3):329-49. doi: 10.1007/BF00046346. Cancer Metastasis Rev. 1996. PMID: 9034595 Review. - Immune responses to tumour antigens: implications for antigen specific immunotherapy of cancer.
Jäger D, Jäger E, Knuth A. Jäger D, et al. J Clin Pathol. 2001 Sep;54(9):669-74. doi: 10.1136/jcp.54.9.669. J Clin Pathol. 2001. PMID: 11533070 Free PMC article. Review. - Expansion of cancer germline antigen-specific cytotoxic T lymphocytes for immunotherapy.
Krishnadas DK, Wang Y, Sundaram K, Bai F, Lucas KG. Krishnadas DK, et al. Tumour Biol. 2017 Jul;39(7):1010428317701309. doi: 10.1177/1010428317701309. Tumour Biol. 2017. PMID: 28677424 - [Tumor rejection antigen and cancer immunotherapy].
Matsutake T, Nakayama E. Matsutake T, et al. Gan To Kagaku Ryoho. 1995 Nov;22(13):1871-7. Gan To Kagaku Ryoho. 1995. PMID: 7487115 Review. Japanese.
Cited by
- Evaluation of the modified ELISPOT assay for gamma interferon production in cancer patients receiving antitumor vaccines.
Asai T, Storkus WJ, Whiteside TL. Asai T, et al. Clin Diagn Lab Immunol. 2000 Mar;7(2):145-54. doi: 10.1128/CDLI.7.2.145-154.2000. Clin Diagn Lab Immunol. 2000. PMID: 10702485 Free PMC article. - Measuring naturally acquired immune responses to candidate malaria vaccine antigens in Ghanaian adults.
Dodoo D, Hollingdale MR, Anum D, Koram KA, Gyan B, Akanmori BD, Ocran J, Adu-Amankwah S, Geneshan H, Abot E, Legano J, Banania G, Sayo R, Brambilla D, Kumar S, Doolan DL, Rogers WO, Epstein J, Richie TL, Sedegah M. Dodoo D, et al. Malar J. 2011 Jun 20;10:168. doi: 10.1186/1475-2875-10-168. Malar J. 2011. PMID: 21689436 Free PMC article. - Single-cell TCRseq: paired recovery of entire T-cell alpha and beta chain transcripts in T-cell receptors from single-cell RNAseq.
Redmond D, Poran A, Elemento O. Redmond D, et al. Genome Med. 2016 Jul 27;8(1):80. doi: 10.1186/s13073-016-0335-7. Genome Med. 2016. PMID: 27460926 Free PMC article. - Evolution of T-cell clonality in a patient with Ph-negative acute lymphocytic leukemia occurring after interferon and imatinib therapy for Ph-positive chronic myeloid leukemia.
Wang L, Zhu K, Zha X, Chen S, Yang L, Chen S, Li Y. Wang L, et al. J Hematol Oncol. 2010 Apr 9;3:14. doi: 10.1186/1756-8722-3-14. J Hematol Oncol. 2010. PMID: 20377918 Free PMC article. - High frequencies of naive Melan-A/MART-1-specific CD8(+) T cells in a large proportion of human histocompatibility leukocyte antigen (HLA)-A2 individuals.
Pittet MJ, Valmori D, Dunbar PR, Speiser DE, Liénard D, Lejeune F, Fleischhauer K, Cerundolo V, Cerottini JC, Romero P. Pittet MJ, et al. J Exp Med. 1999 Sep 6;190(5):705-15. doi: 10.1084/jem.190.5.705. J Exp Med. 1999. PMID: 10477554 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources